<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More


Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More


Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More


Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More


Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More


Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More


Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More


Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More


Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More


Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More


Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

Breast Cancer No Longer Scary as we Reveal Its Smarter Disguises

October is breast cancer awareness month and CrownBio has reviewed the latest breast cancer research to bring you the highlights of recent preclinical advances

Breast cancer is the leading type of cancer diagnosed in women worldwide, accounting for 25% of all cancer cases and resulting in over half a million deaths per year. Although the rate of success in curing breast cancer has steadily improved over the past 15 years, some patients still relapse with metastatic disease, which is much more difficult to eradicate because it presents with a more heterogeneous set of cancer cell types.

Further research is needed to unravel the complexity behind the tumor heterogeneity in metastatic breast cancer, and to translate this into new therapeutic options.

A study led by Harvard Medical School investigators at Massachusetts General Hospital has recently found that the molecular characteristics of breast cancer cells can spontaneously change in patients with metastatic disease, leading to tumors with a mixed population of cells.

This preclinical finding is bound to influence decisions made at the clinical stage because, as tumors evolve, so should the therapeutic approach, requiring combinations of several types of targeted drugs.

To test various combinations of therapies and ensure a greater chance of success with patients in the clinic, better preclinical models are required that mimic patients tumors and could be used to evaluate treatment efficacy.

Another aspect of tumor heterogeneity is represented by the presence at the breast tumor site of healthy cells from the immune system. These cells are thought to be there to try and fight cancer growth. However, tumor cells have found ways to stop immune cells from performing their normal functions, enabling cancer growth and progression.

In a paper published in the journal Nature Immunology a group of researchers from King’s College London discovered that immune cells recruited to the site of a breast tumor not only are no longer able to kill the tumor, but are also highjacked by cancer cells into producing factors that promote tumor growth and movement.

This is due to the interaction between two factors: a class of proteins called mucins (MUC1) on the surface of cancer cells and a protein called lectin (Singlec-9) on the immune cells. MUC1 is also able to induce the expression of PD-L1 in immune cells, a receptor that has been successfully targeted by immunotherapy in several types of cancer.

These findings could lead to the development of a new targeted treatment for breast cancer patients, which works by blocking the MUC1/Singlec-9 interaction. The new experimental agents could then be combined with anti-PD-L1 drugs that have already shown efficacy in lung and skin cancer patients.

The next step for developing this kind of treatment would be testing in vivo, which requires a collection of well-characterized and validated breast cancer models for various stages of drug efficacy research.

If the preclinical in vivo work shows successful results, it could then progress to clinical trials in humans.

Crown Bioscience believes it is vital that these basic research findings are followed up by preclinical work to develop and test the next generation of anticancer drugs before they reach patients in the clinic.

To help breast cancer drug development CrownBio has a wealth of well-characterized and validated models readily available for every stage of drug discovery, from early efficacy and pharmacodynamics research in cell linesto later stage in vivo cell line derived and patient-derived xenograft (PDX) models.

To help accelerate the development of the latest breast cancer immunotherapy agents, CrownBio provides a collection of models for in vitro and in vivo efficacy testing as well as large scale screening services on a panel of well-characterized syngeneic models.

Last but not least, our research and development teams have made great progress in refining the use of humanized PDX and cell line derived xenograft models for application to late stage immunotherapy drug discovery programs.

Contact us today to discover more on all our breast cancer research platforms.

Related Posts